RxDoctor Payments Data

Arnaldo Nieves Ortiz, MD

Internal Medicine · Caguas, PRNPI 1730548967

Payments from drug & device makers

$2,636in general payments, 2019–2025

Across 74 payments — averaging $35.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$408
  • AstraZeneca$322
  • Johnson & Johnson$308
  • Merck$300
  • E.r. Squibb & Sons, L.L.C.$136
  • GSK$125
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$2,636100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,636 in reported general payments places this provider in the 80th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$6,943
Medicare patients
12
Services billed
81

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin167$105,494
EliquisApixaban85$50,529
BrilintaTicagrelor39$17,705
EntrestoSacubitril/Valsartan22$15,223
FarxigaDapagliflozin Propanediol14$8,213
XareltoRivaroxaban13$7,506
Metoprolol Succinate196$1,641
Atorvastatin Calcium205$1,416
Amiodarone Hcl53$1,084
CefuroximeCefuroxime Axetil43$935
LantusInsulin Glargine,hum.Rec.Anlog11$840
SynthroidLevothyroxine Sodium17$806
Bumetanide27$776
Famotidine140$751
Spironolactone110$717

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$408$105,494167 claims
AstraZenecaBrilinta, Farxiga$322$25,91953 claims
NovartisEntresto$45$15,22322 claims
Johnson & JohnsonXarelto$308$7,50613 claims
Sanofi-aventis U.S. LLCLantus$65$84011 claims
AbbVieSynthroid$23$80617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in Caguas

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →